Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: A novel study design in a large Italian AIEOP cohort

Pharmacogenomics

Volumn 13, Issue 16, 2012, Pages 1905-1916

  Franca, Raffaella ^a   Rebora, Paola ^b   Basso, Giuseppe ^c   Biondi, Andrea ^b   Cazzaniga, Giovanni ^a   Crovella, Sergio ^d   Decorti, Giuliana ^e   Fagioli, Franca ^f   Giarin, Emanuela ^c   Locatelli, Franco ^g   Poggi, Vincenzo ^g   Valsecchi, Maria Grazia ^b   Rabusin, Marco ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g Santobono Pausilipon Children Hospital   (Italy)

Author keywords

acute lymphoblastic leukemia; glutathione S transferase; polymorphisms; prognostic genetic factors; relapse; risk adapted polychemotherapy; two phase design

Indexed keywords

GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENE DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUTATHIONE TRANSFERASE M1 GENE; GLUTATHIONE TRANSFERASE T1 GENE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRESCHOOL CHILD; SCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GENOTYPE; GLUTATHIONE TRANSFERASE; HOMOZYGOTE; HUMANS; INFANT; ITALY; KAPLAN-MEIER ESTIMATE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TREATMENT OUTCOME;

EID: 84870785279     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.169     Document Type: Article

References (43)

1. Conter V, Arico M, Valsecchi MG et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 14, 2196-2204 (2000).
2. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120(6), 1165-1174 (2012).
3. Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000. study. Blood 118(8), 2077-2084 (2011).
4. Gaynon PS. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. Curr. Hematol. Malig. Rep. 2, 193-201 (2007).
5. Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin. Pharmacol. Ther. 90, 461-466.
6. Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin. Oncol. 38, 186-195 (2011).
7. Townsend D, Tew K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3, 157-172 (2003).
8. Nakagawa K, Saijo N, Tsuchida S et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J. Biol. Chem. 265, 4296-4301 (1990).
9. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54, 4313-4320 (1994).
10. Yuan ZM, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab. Dispos. 19, 625-629 (1991).
11. Black SM, Beggs JD, Hayes JD et al. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem. J. 268, 309-315 (1990).
12. Dirven HA, Megens L, Oudshoorn MJ, Dingemanse MA, van Ommen B, van Bladeren PJ. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol. 8, 979-986 (1995).
13. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 6, 163-173 (1992).
14. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30, 445-600 (1995).
15. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375 (2003).
16. O'Dwyer PJ, Hamilton TC, Yao KS, Tew KD, Ozols RF. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol. Oncol. Clin. North Am. 9, 383-396 (1995).
17. Garte S, Gaspari L, Alexandrie AK et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10, 1239-1248 (2001).
18. Pemble S, Schroeder KR, Spencer SR et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300, 271-276 (1994).
19. Anderer G, Schrappe M, Brechlin AM et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 10, 715-726 (2000).
20. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95, 1222-1228 (2000).
21. Takanashi M, Morimoto A, Yagi T et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 88, 1238-1244 (2003).
22. Davies SM, Bhatia S, Ross JA et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100, 67-71 (2002).
23. Krajinovic M, Labuda D, Mathonnet G et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. 8, 802-810 (2002).
24. Goasguen JE, Lamy T, Bergeron C et al. Multifactorial drug-resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome. Leuk. Lymphoma 23, 567-576 (1996).
25. Reilly M. Optimal sampling strategies for two-stage studies. Am. J. Epidemiol. 143, 92-100 (1996).
26. Flohr T, Schrauder A, Cazzaniga G et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000. for childhood acute lymphoblastic leukemia. Leukemia 22, 771-782 (2008).
27. Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184. patients of the AIEOP-BFM ALL 2000. study. Blood 115, 3206-3214 (2010).
28. Lumley T. Complex Surveys: a Guide to Analysis using R. Couper MP, Kalton G, Rao JNK, Schartz N, Skinner C, Groves RM (Eds). John Wiley and sons Inc., NJ, USA (2010).
29. Breslow NE, Wellner JA. A Z-theorem with estimated nuisance parameters and correction note for 'weighted likelihood for semiparametric models and two-phase stratified samples, with application to Cox regression'. Scand. Stat. Theory Appl. 35, 186-192 (2008).
30. Chen CL, Liu Q, Pui CH et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 89, 1701-1707. (1997).
31. Meissner B, Stanulla M, Ludwig WD et al. The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia 18, 1920-1923 (2004).
32. Rocha JC, Cheng C, Liu W et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105, 4752-4758 (2005).
33. Sala A, Lanciotti M, Valsecchi MG et al. Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. Leukemia 17, 981-983 (2003).
34. Scheike TH, Juul A. Maximum likelihood estimation for Cox's regression model under nested case-control sampling. Biostatistics 5, 193-206 (2004).
35. Hosono N, Kishi S, Iho S et al. Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line. Cancer Sci. 101, 767-773 (2010).
36. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61, 154-166 (2000).
37. Josephy PD. Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Hum. Genomics Proteomics 2012, 876940. (2010).
38. Thorn CF, Ji Y, Weinshilboum RM, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet. Genomics 22, 646-651 (2012).
39. Bruhn C, Brockmoller J, Kerb R, Roots I, Borchert HH. Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Biochem. Pharmacol. 56, 1189-1193 (1998).
40. Buchard A, Sanchez JJ, Dalhoff K, Morling N. Multiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant. J. Mol. Diagn. 9, 612-617 (2007).
41. Sprenger R, Schlagenhaufer R, Kerb R et al. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 10, 557-565 (2000).
42. Timofeeva M, Jager B, Rosenberger A et al. A multiplex real-time PCR method for detection of GSTM1 and GSTT1 copy numbers. Clin. Biochem. 42, 500-509 (2009).
43. Borst L, Buchard A, Rosthoj S et al. Gene dose effects of GSTM1, GSTT1 and GSTP1 polymorphisms on outcome in childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 34(1), 38-42 (2012).